T1	Participants 68 95	nocturnal sleep disruption:
T2	Participants 140 165	patients with narcolepsy.
T3	Participants 269 288	narcolepsy patients
T4	Participants 368 454	228 adult patients with narcolepsy/cataplexy in the United States, Canada, and Europe.
T5	Participants 622 653	receiving 6 and 9 g/night doses
